PharmaCyte Biotech, Inc. (PMCB) shareholders
PMCBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
$6.68−0.92 (-12.11%)
Close on Nov 13, 2026Market cap $71.71MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
7.1%
1M of 11M shares
Institutional holders
28
2 new, 5 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
6 buys · 0 sales
Net bought $128.50K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Waqas Khatri Joint filing with Ayrton Capital LLC (9.90%), Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B (9.90%) | 774,100 | 9.90% | 13G (passive) amendment | Dec 31, 2024 |
| Mitchell P. Kopin Joint filing with Intracoastal Capital LLC (9.99%), Daniel B. Asher (9.99%) | 695,715 | 9.99% | 13G (passive) amendment | Sep 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PMCB | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Citadel Advisors LLC | 283,381 | 2.64% | $218.20K | −76,166 | 0.00% |
| Geode Capital Management, LLC | 124,247 | 1.16% | $95.68K | −71,413 | 0.00% |
| Vanguard Capital Management LLC | 56,778 | 0.53% | $43.72K | +5,311 | 0.00% |
| Susquehanna International Group, Llp | 44,853 | 0.42% | $34.54K | New | 0.00% |
| Renaissance Technologies LLC | 37,987 | 0.35% | $29.25K | −18,513 | 0.00% |
| XTX Topco Ltd | 34,180 | 0.32% | $26.32K | −18,182 | 0.00% |
| Northern Trust Corp | 32,624 | 0.30% | $25.12K | −2,977 | 0.00% |
| Jane Street Group, LLC | 30,064 | 0.28% | $23.15K | +18,534 | 0.00% |
| Schonfeld Strategic Advisors LLC | 26,926 | 0.25% | $20.73K | −83 | 0.00% |
| Vanguard Fiduciary Trust Co | 23,452 | 0.22% | $18.06K | – | 0.00% |
| Equitec Proprietary Markets, LLC | 22,227 | 0.21% | $17.12K | – | 0.00% |
| Commonwealth Equity Services, LLC | 20,255 | 0.19% | $15.60K | +9,942 | 0.00% |
| Hrt Financial LP | 15,451 | 0.14% | $11.00K | −9,290 | 0.00% |
| Tower Research Capital LLC (TRC) | 4,888 | 0.05% | $3.76K | −1 | 0.00% |
| UBS Group AG | 4,142 | 0.04% | $3.19K | −377 | 0.00% |
| Group One Trading, L.P. | 500 | 0.00% | $385 | −1,285 | 0.00% |
| Osaic Holdings, Inc. | 303 | 0.00% | $232 | +1 | 0.00% |
| Covestor Ltd | 275 | 0.00% | $0 | – | 0.00% |
| Barclays PLC | 192 | 0.00% | $148 | New | 0.00% |
| Sachetta, LLC | 14 | 0.00% | $11 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 28 | 1M | 7.1% | 2 / 6 | 10 / 5 | 0M | 0M |
| Q1 2026 | 32 | 1M | 9.0% | 9 / 6 | 7 / 4 | 0M | 0M |
| Q4 2025 | 28 | 1M | 9.2% | 7 / 5 | 7 / 1 | 1M | 0M |
| Q3 2025 | 23 | 0M | 4.0% | 6 / 3 | 4 / 6 | 0M | 0M |
| Q2 2025 | 23 | 1M | 5.4% | 2 / 6 | 3 / 3 | 0M | 0M |
| Q1 2025 | 24 | 1M | 5.3% | 4 / 4 | 8 / 1 | 0M | 0M |
| Q4 2024 | 21 | 1M | 5.6% | 1 / 2 | 10 / 5 | 0M | 0M |
| Q3 2024 | 26 | 1M | 7.7% | 2 / 3 | 10 / 3 | 0M | 0M |
| Q2 2024 | 28 | 1M | 9.6% | 3 / 10 | 9 / 3 | 0M | 0M |
| Q1 2024 | 29 | 1M | 9.1% | 1 / 9 | 9 / 4 | 0M | 0M |
| Q4 2023 | 32 | 1M | 10.1% | 5 / 11 | 8 / 3 | 0M | 0M |
| Q3 2023 | 31 | 1M | 10.6% | 4 / 8 | 9 / 2 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
5 funds held PMCB in Q2 2026, 27% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of PMCB | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 101,568 | 0.95% | $84.75K | 0.00% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 56,778 | 0.53% | $43.72K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 26,211 | 0.24% | $21.87K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 15,256 | 0.14% | $12.73K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 12,896 | 0.12% | $10.76K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Joshua Silverman | CEO and President, Director | 466,250 | 4.34% | Jan 7, 2026 |
| Wayne Remell Walker | Director | 37,500 | 0.35% | Jul 17, 2026 |
| Robert Weinstein | Director | 41,250 | 0.38% | Jul 17, 2026 |
| Michael M. Abecassis | Director | 23,092 | 0.22% | Jul 17, 2026 |
| Jonathan Schechter | Director | 192,500 | 1.79% | Jul 17, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jonathan Schechter Director | Jan 7, 2026 | Buy | +20,000 | $0.84 | $16.80K | 192,500 |
| Joshua Silverman CEO and President, Director | Jan 7, 2026 | Buy | +40,000 | $0.83 | $33.20K | 416,250 |
| Jonathan Schechter Director | Jan 6, 2026 | Buy | +20,000 | $0.79 | $15.80K | 172,500 |
| Joshua Silverman CEO and President, Director | Jan 6, 2026 | Buy | +30,000 | $0.79 | $23.70K | 376,250 |
| Jonathan Schechter Director | Jan 5, 2026 | Buy | +20,000 | $0.78 | $15.60K | 152,500 |
| Joshua Silverman CEO and President, Director | Jan 5, 2026 | Buy | +30,000 | $0.78 | $23.40K | 346,250 |
| Wayne Remell Walker Director | Dec 12, 2025 | Award | +37,500 | – | – | 37,500 |
| Wayne Remell Walker Director | Dec 12, 2025 | Tax withholding | −16,875 | $1.02 | $17.21K | 20,625 |
| Joshua Silverman CEO and President, Director | Dec 12, 2025 | Tax withholding | −258,750 | $1.02 | $263.93K | 316,250 |
| Joshua Silverman CEO and President, Director | Dec 12, 2025 | Award | +575,000 | – | – | 575,000 |
| Robert Weinstein Director | Dec 12, 2025 | Tax withholding | −33,750 | $1.02 | $34.43K | 41,250 |
| Robert Weinstein Director | Dec 12, 2025 | Award | +75,000 | – | – | 75,000 |
| Michael M. Abecassis Director | Dec 12, 2025 | Tax withholding | −16,875 | $1.02 | $17.21K | 22,292 |
| Michael M. Abecassis Director | Dec 12, 2025 | Award | +37,500 | – | – | 39,167 |
| Jonathan Schechter Director | Dec 12, 2025 | Award | +150,000 | – | – | 200,000 |
| Jonathan Schechter Director | Dec 12, 2025 | Tax withholding | −67,500 | $1.02 | $68.85K | 132,500 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
0.51%
0M shares short
Days to cover
1.2
At 0M shares a day
Change since last report
-27.7%
From 0M shares
Short volume, 20 days
27.4%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of PharmaCyte Biotech's stock actually held short. Settlement fails (shares not delivered on time) peaked at 3 shares on Sep 17, 2026 over the last 90 days.
See a number that looks wrong?